Autosomal dominant polycystic kidney disease.
Cornec-Le Gall E, Alam A, Perrone RD.
Lancet. 2019 Mar 2;393(10174):919-935. doi: 10.1016/S0140-6736(18)32782-X. Epub 2019 Feb 25.
Autosomal dominant polycystic kidney disease.
Torres VE, Harris PC, Pirson Y.
Lancet. 2007 Apr 14;369(9569):1287-1301. doi: 10.1016/S0140-6736(07)60601-1.
Autosomal Dominant Polycystic Kidney Disease.
Suarez MLG, Titan S, Dahl NK.
Adv Kidney Dis Health. 2024 Nov;31(6):496-503. doi: 10.1053/j.akdh.2024.07.003.
Autosomal Dominant Polycystic Kidney Disease.
Perumareddi P, Trelka DP.
Prim Care. 2020 Dec;47(4):673-689. doi: 10.1016/j.pop.2020.08.010.
Autosomal Dominant Polycystic Kidney Disease: From Pathophysiology of Cystogenesis to Advances in the Treatment.
Reiterová J, Tesař V.
Int J Mol Sci. 2022 Mar 19;23(6):3317. doi: 10.3390/ijms23063317.
Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2025.
Gordon CE, Garimella PS, Perrone RD, Miskulin DC.
Am J Kidney Dis. 2025 Oct;86(4):525-542. doi: 10.1053/j.ajkd.2025.05.010. Epub 2025 Aug 22.
Therapies in autosomal dominant polycystic kidney disease: beyond tolvaptan.
Fang C, Norouzi S, Garimella PS.
Curr Opin Nephrol Hypertens. 2025 Sep 1;34(5):368-374. doi: 10.1097/MNH.0000000000001101. Epub 2025 Jul 4.
Nonpharmacological Management of Autosomal Dominant Polycystic Kidney Disease.
Steele CN, Nowak KL.
Adv Kidney Dis Health. 2023 May;30(3):220-227. doi: 10.1053/j.akdh.2022.12.008.
Polycystic Kidney/Liver Disease.
Roediger R, Dieterich D, Chanumolu P, Deshpande P.
Clin Liver Dis. 2022 May;26(2):229-243. doi: 10.1016/j.cld.2022.01.009. Epub 2022 Apr 1.
Drug repurposing in autosomal dominant polycystic kidney disease.
Zhou JX, Torres VE.
Kidney Int. 2023 May;103(5):859-871. doi: 10.1016/j.kint.2023.02.010. Epub 2023 Mar 2.
